Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.7 USD | -0.57% | -3.62% | +4.36% |
04-30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
04-29 | Health Care Up on Growth Optimism -- Health Care Roundup | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 31.12 and 24.14 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.36% | 288B | C+ | ||
+33.25% | 704B | C+ | ||
+28.59% | 577B | B | ||
-3.55% | 348B | C+ | ||
+18.16% | 327B | B- | ||
+14.81% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.69% | 147B | C+ | ||
-5.59% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- Ratings AbbVie Inc.